Beam Therapeutics (BEAM)
Develops base-edited medicines for sickle cell disease and inherited metabolic disorders.
Something off on this page? Send us feedback.
Develops base-edited genetic medicines led by risto-cel for sickle cell disease and BEAM-302 for alpha-1 antitrypsin deficiency, alongside earlier liver-targeted programs. Revenue comes from licenses and collaborations rather than product sales, while development spans ex vivo cell therapy and in vivo lipid-nanoparticle delivery.
Develops investigational genetic medicines using base editing, which makes targeted single-letter DNA changes without double-stranded breaks. The hematology franchise centers on risto-cel, an autologous cell therapy for sickle cell disease. The liver-targeted genetic disease franchise includes BEAM-302 for alpha-1 antitrypsin deficiency, BEAM-301 for glycogen storage disease type Ia, and BEAM-304 for phenylketonuria, using lipid-nanoparticle delivery for in vivo editing.
Combines editing, delivery, clinical development, and internal manufacturing capabilities across U.S. operations in Massachusetts and North Carolina. No medicine has been approved for sale, and revenue to date has come primarily from licensing and collaboration agreements. Progress depends on clinical results, regulatory approval, reliable manufacturing and delivery, collaboration terms, and intellectual-property protection; the business is managed as one operating and reportable segment.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| May 21, 2026 | H.C. Wainwright | Target | Target: — | Target: $80 |
| May 13, 2026 | Tudor Pickering | Target | Target: $41 | Target: $39 |
| Feb 25, 2026 | RBC Capital | Reiterate | Rating: —Target: — | Target: $26 |
| Feb 20, 2026 | Canaccord Genuity | Target | Target: — | Target: $74 |
| Jan 21, 2026 | Tudor Pickering | Target | Target: $37 | Target: $41 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $1.15B · Total debt $247.4M · Total assets $1.39B · Shareholders' equity $1.07B
- Revenue
- $490.0K
- Operating income
- −$126.6M
- Net income
- −$122.7M
No dividends on record.
| Institutions | ≈ 106.15% | 109.64M shares | |
|---|---|---|---|
| 286 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 0.59% | 605.9K shares | |
| 5 holders · as of Jul 29, 2026 | |||
| Adds to | 106.74% | ||
103.29M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 106.74%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
FMR LLCInstitution | 12.21% | 12.61M | as of Jun 30, 2026 |
Farallon Capital Management LLCInstitution | 9.91% | 10.24M | as of Jun 30, 2026 |
Ark Investment Management LLCInstitution | 9.91% | 10.23M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 8.71% | 9.00M | as of Jun 30, 2026 |
State Street CorpInstitution | 5.64% | 5.83M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 27, 2026 | Amy Simon | officer: Chief Medical Officer | −16,667 | $25.74 |
| Jun 30, 2026 | Amy Simon | officer: Chief Medical Officer | −373 | $34.73 |
| Jun 29, 2026 | John M. Evans | director, officer: CEO | −25,000 | $35.49 |
| Jun 30, 2026 | John M. Evans | director, officer: CEO | −25,000 | $34.31 |
| Jun 26, 2026 | FMR LLC | 10 percent owner, other: See Remark 1 | −251,488 | $35.26 |
- CRISPR Therapeutics
Approved CRISPR SCD therapy and platform benchmark for risto-cel
- Vertex Pharmaceuticals
Commercial CASGEVY owner with SCD access and reimbursement leverage
- Wave Life Sciences
RNA-editing AATD program challenging BEAM-302's root-cause claim
- Arrowhead Pharmaceuticals
Phase 3 RNAi AATD asset competing with BEAM-302 on liver disease
- Intellia Therapeutics
Late-stage in vivo CRISPR benchmark for systemic editing
- Prime Medicine
Prime-editing AATD and liver programs pressure base-editing claims
- Regeneron
Partnered AATD Gene Writing asset backed by large-cap scale
- Editas Medicine
In vivo CRISPR pivot keeps pressure on next-wave SCD editing
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Beam Therapeutics | $26.02 | +2.99% | $2.60B | — | — | 16.7 | −94.2% |
| CRISPR Therapeutics | $59.18 | +1.46% | $5.63B | — | — | 420.1 | +1,041.4% |
| Vertex Pharmaceuticals | $518.60 | +1.54% | $129.62B | 29.7 | 27.0 | 10.3 | +12.5% |
| Wave Life Sciences | $4.38 | +2.82% | $838.4M | — | — | 12.8 | −73.9% |
| Arrowhead Pharmaceuticals | $71.91 | +4.53% | $9.69B | — | — | 14.5 | +171.0% |
| Intellia Therapeutics | $12.76 | +4.43% | $1.71B | — | — | 28.7 | −46.2% |
| Prime Medicine | $3.55 | +11.13% | $576.2M | — | — | 141.5 | +3.5% |
| Regeneron | $808.87 | +1.34% | $82.23B | 19.7 | 13.4 | 5.3 | +16.7% |
| Editas Medicine | $2.91 | +2.83% | $434.3M | — | — | 9.2 | +232.3% |
| Median | 24.7 | 20.2 | 13.6 | +14.6% |